化疗联合免疫活性细胞治疗中晚期非小细胞肺癌的疗效观察  

Chemotherapy combined with immunotherapy in treatment of middle and advanced stage non-small cell lung cancer

作　　者：张建刚[1] 叶知锋[1] 黄伶[1] 黄挺[1] 张志娣[1] 

机构地区：[1]杭州市中医院肿瘤科,310007

出　　处：《中华内分泌外科杂志》2015年第6期504-507,共4页Chinese Journal of Endocrine Surgery

摘　　要：目的研究分析化疗联合免疫活性细胞治疗对中晚期非小细胞肺癌的疗效及患者生活质量改善情况。方法选择2012年3月至2014年3月在杭州市中医院接受治疗的140例中晚期非小细胞肺癌患者，随机分为观察组70例，对照组70例，观察组采取化疗联合免疫治疗，对照组则采取单纯化疗。对比分析2组的生活质量、治疗效果及免疫指标的变化情况等。结果观察组的生活质量提高率（90．0％）明显高于对照组（54．3％），2组差异有统计学意义（P〈0.05）；观察组治疗的有效率（88．6％）明显高于对照组（70．0％），2组差异有统计学意义（P〈0．05）；观察组在治疗后CD3^＋、CD4^＋、CD8^＋细胞的百分率及CD4^＋／CD8^＋细胞百分率的提高程度明显高于对照组，2组差异存在统计学意义（P〈0．05）。结论化疗联合免疫免疫活性细胞治疗中晚期非小细胞肺癌患者效果明显，安全性高，临床价值高。Objective To study the efficacy of chemotherapy combined with immunotherapy in treatment of middle and advanced stage non-small cell lung cancer and improvement of patients＇ life quality. Methods 140 patients with middle and advanced stage non-small cell lung cancer treated from Mar. 2012 to Mar. 2014 were in- eluded and they were randomly divided into two groups：the observation group（ 70 cases）and the control group（ 70 cases）. The observation group took chemotherapy combined with immunotherapy, while the control group took chemotherapy treatment alone. Patients＇ life quality, treatment effects and changes in immune indexes were co- mared between the two groups. Results The improvement rate of life quality of the observation group（90.0% ） was significantly higher than that of the control group（58.6% ） , and the difference had satistical significance（ P 〈 0.05 ）. The response rate of the observation group （ 88.6% ） was significantly higher than that of the control group（70. 0% ）, and the difference had statistical significance（P 〈 0. 05 ）. The increasement rate of CD3^＋, CD^＋ , CD8^＋ cells, as well as CD4^＋/CD8^＋ cells was significantly higher in the observation group than in the control group, and the difference had statistical significance （ P 〈 0. 05 ）. Conclusion Chemotherapy combined with immunotherapy in teatment of patients with middle and advanced non-small cell lung cancer has obvious effect, high safety, and high clinical value.

关 键 词：化疗 免疫治疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]